BD (Becton, Dickinson and Company) announced on July 23, 2025, the initiation of the first pharma-sponsored combination product clinical trial utilizing its BD Libertas™ Wearable Injector. This trial focuses on the subcutaneous delivery of complex biologic drugs.
The selection of the BD Libertas™ Wearable Injector for this trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies. A device clinical study demonstrated excellent performance, with 100% of participants indicating they would likely use the injector if prescribed.
This trial represents a significant advancement in accelerating innovation in drug-device combination products, offering greater flexibility for patients. It supports the potential conversion of infused medications to more convenient self-injection options at home, tapping into the biologics market expected to exceed $670 billion by 2030.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.